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AbstrACt
Objectives The objective of this study was to determine 
the availability and prices of medicines for non- 
communicable diseases (NCDs) in health facilities and 
private for- profit drug outlets in Kenya.
Design Cross- sectional study.
Methods All public and non- profit health facilities in eight 
counties (Embu, Kakamega, Kwale, Makueni, Narok, Nyeri, 
Samburu and West Pokot) that purchased medicines from 
the Mission for Essential Drugs and Supplies, a major 
wholesaler, were surveyed in September 2016. For each 
health facility, one nearby private for- profit drug outlet was 
also surveyed. Data on availability and price were analysed 
for 24 NCD and 8 acute medicine formulations. Availability 
was analysed separately for medicines in the national 
Essential Medicines List (EML) and those in the Standard 
Treatment Guidelines (STGs). Median price ratios were 
estimated using the International Medical Products Price 
Guide as a reference.
results 59 public and 78 non- profit facilities and 135 
drug outlets were surveyed. Availability of NCD medicines 
was highest in private for- profit drug outlets (61.7% and 
29.3% for medicines on the EML and STGs, respectively). 
Availability of STG medicines increased with increasing 
level of care of facilities: 16.1% at dispensaries to 31.7% 
at secondary referral facilities. The mean proportion of 
availability for NCD medicines listed in the STGs (0.25) 
was significantly lower than for acute medicines (0.61), 
p<0.0001. The proportion of public facilities giving 
medicines for free (0.47) was significantly higher than the 
proportion of private non- profit facilities giving medicines 
for free (0.09) (p<0.0001). The mean price ratio of 
NCD medicines was significantly higher than for acute 
medicines in non- profit facilities (4.1 vs 2.0, respectively; 
p=0.0076), and in private for- profit drug outlets (3.5 vs 
1.7; p=0.0013).
Conclusion Patients with NCDs in Kenya appear to have 
limited access to medicines. Increasing access should be a 
focus of efforts to achieve universal health coverage.
IntrODuCtIOn
The burden of non- communicable diseases 
(NCDs) has been on the rise, especially in 
low/middle- income countries (LMICs).1 2 
Globally, an estimated 40.5 million deaths in 
2016 were due to NCDs.2 Eighty per cent of 
these deaths were caused by diseases including 
cancers, cardiovascular diseases (CVD), 
chronic respiratory diseases and diabetes. 
Nearly 80% of NCD deaths occur in LMICs, 
and people living in sub- Saharan Africa face 
the highest risk of death.2 3 In Kenya, one- half 
of total hospital admissions and over 55% of 
hospital deaths are due to NCDs.4 Cardiovas-
cular diseases are the leading cause of NCD 
related deaths followed by cancer, which 
accounts for 7% of overall mortality in the 
country.5 According to the Kenya Stepwise 
strengths and limitations of this study
 ► To the best of our knowledge this is the first study 
to evaluate availability of medicines based on the 
level of care medicines are assigned in the national 
Essential Medicines List (EML).
 ► This study also evaluated availability separately for 
medicines for non- communicable diseases includ-
ed in the EML and those included in the Standard 
Treatment Guidelines, highlighting the crucial differ-
ences between the two service delivery documents.
 ► The cross- sectional study design did not allow us 
to assess trends in availability and price of medi-
cines over time and precludes making strong causal 
inferences.
 ► Availability of medicines was evaluated as binary 
variable (yes/no) and did not count the quantity in 
stock.
 ► The sample of participating private for- profit drug 
outlets was restricted to those nearest to public and 
non- profit facilities. While this may not be represen-
tative of all private for- profit sector facilities, it gave 
us the opportunity to study the availability and pric-
es consumers would encounter when referred from 
public and non- profit facilities.
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Survey for Non- communicable Diseases Risk Factors 
2015 Report, the prevalence of hypertension stands at 
24%.4 With a national prevalence of about 4%, diabetes 
accounts for more than 8000 deaths annually in Kenya.6 7
In 2011, the United Nations General Assembly adopted 
a resolution for the prevention and control of NCDs.8 
This commitment was renewed in 2015 with the adoption 
of the sustainable development goals (SDGs), target 3.4 
of which aims to ‘by 2030, reduce by one- third premature 
mortality from NCDs through prevention and treatment 
and promote mental health and well- being’.9 In 2014, 
Kenya launched its National Health Policy with the goal 
of attaining the ‘highest possible standard of health in 
a responsive manner’.10 Among the six key objectives of 
this policy, one directly targets NCDs: ‘halt and reverse 
the rising burden of non- communicable conditions’.
Two critical indicators listed in the global monitoring 
framework for the prevention and control of NCDs 
adopted by the 66th World Health Assembly in 2013 
include affordability and availability of NCD medicines in 
health facilities.11 12
Several studies have demonstrated limited availability 
and affordability of NCD medicines in LMICs.13–15 
Despite the high burden of NCDs in Kenya, there 
are many challenges regarding access to NCD medi-
cines.4 16 17 The government owned Kenya Medical 
Supplies Agency and the Mission for Essential Drugs 
and Supplies (MEDS), are the leading suppliers (whole-
salers) of medicines to public and non- profit hospitals 
and clinics. MEDS, a faith- based organisation, supply 
about 40% of the volume of medicines consumed at 
public and non- profit facilities and operates in about 33 
of the 47 counties in the country,18 stockouts at these two 
wholesalers have reportedly been minimal.19 However, 
the availability of medicines in health facilities that serve 
patients (including dispensaries, health centres and 
hospitals) is generally poor, which may be a reflection 
of the supplier—retailer supply chain weaknesses and 
public financing of medicines among other factors.20 
Medicines for NCDs were found to be much less available 
at health facilities compared with medicines for commu-
nicable diseases (46% vs 70%).20 The Kenya Service 
Delivery and Readiness Assessment Report, published in 
2014, reported an even lower mean availability of NCD 
medicines at primary care facilities and hospitals: 25% 
and 32%, respectively.21
There is no pricing policy or the regulation of mark- ups 
on medicines in Kenya. The country implemented a 
reduced user fee policy in 2004 which among other 
things, includes providing medicines for free at levels 2 
and 3 facilities.19 22 However, studies have shown poor 
adherence to this policy.22 23 Only 19% of the popula-
tion has insurance coverage, hence most patients pay 
for medicines out- of- pocket.24 Based on data collected in 
2009, the prices of medicines are lower in public facilities 
compared with faith based facilities, though stock- outs 
are about three times more common in public facilities 
(46% vs 14%).19
Previous studies on availability and price of medicines 
in Kenya have had two major limitations. First, these did 
not take into account the level of care of health facilities 
surveyed. With the goal of ensuring appropriate use of 
medicines at various levels of care, the national Essential 
Medicines List (EML), which guides public procurement 
in Kenya restricts most NCD medicines to level 4 facili-
ties (primary (county) referral hospitals) and above.25 26 
However, it is not clear if providers or suppliers follow this 
restriction. Based on this restriction, the free medicines 
policy at lower levels of care and possibly other factors, 
availability and prices of medicines might differ by level of 
care. Second, previous studies did not evaluate availability 
of medicines in the EML separately from medicines in 
the National Standard Treatment Guidelines (STGs). 
Even though the EML and STGs are meant to comple-
ment each other in standardising the provision of quality 
health services in Kenya, there are more medicines listed 
in the STGs than in the EML which can make the stan-
dardisation of care challenging.25–30
The objective of this study was to determine the avail-
ability and price of medicines for NCDs in health facili-
ties and private for- profit drug outlets in Kenya. The study 
compared the availability and prices of NCD medicines to 
acute medicines in order to highlight potential gaps in 
the delivery of NCD services. By taking into account the 
EML restrictions discussed above, and the level of care of 
health facilities surveyed, this study highlights the dispari-
ties in access to medicines by level of care. Because of the 
inconsistency between the EML and STGs, the study also 
evaluates separately, the availability of medicines included 
in the EML and availability of medicines included in the 
STGs. Findings from this study complement existing 
evidence on the availability and price of NCD medicines 
in LMICs, which is necessary to inform the design of poli-
cies to enhance access to medicines.13 20 21 31–34
MethODs
study setting
The data presented in this paper were collected during 
the baseline study on the evaluation of Novartis Access, 
a low- cost NCD medicines programme implemented by 
Novartis Pharmaceuticals.18 35Novartis Access targets medi-
cines for four NCDs—cardiovascular disease (dyslipi-
daemia, heart failure and hypertension), diabetes, asthma 
and breast cancer. Data were collected from eight study 
counties—Embu, Kakamega, Kwale, Makueni, Narok, 
Nyeri, Samburu and West Pokot. These counties were a 
mix of semiurban and rural areas with a total population 
of 7 million inhabitants, representing 15% of the national 
population.36 These counties were selected based on their 
patronage of medicines from MEDS, and safety for field 
data collection. The selection of these counties had been 
described in more detail by Rockers et al.18
Health facilities (public and private non- profit facili-
ties) in Kenya are hierarchically classified into dispensa-
ries (level 2), health centres (level 3), primary (county) 
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referral hospitals (level 4), secondary referral hospitals 
(level 5) and tertiary hospitals (level 6).10 Dispensaries 
are the lowest level of care and offer treatment for simple 
ailments to outpatients, antenatal care and so on, while 
tertiary hospitals are the highest level of care and offer 
more specialised services.37 38
Data collection
Data were collected in September 2016 by trained data 
collectors in English language, using study instrument 
programmed in the software application, Survey CTO.39 
The study instrument was pilot tested twice by the trained 
data collectors and revised based on the feedback received 
from each pilot test.
All of the public and private non- profit health facilities 
(level 2–level 5) in eight counties that purchase medi-
cines through MEDS were surveyed. No level 6 facility was 
included in the study. After data collection at each health 
facility, data collectors asked respondents to identify the 
nearest private for- profit drug outlet where patients are 
referred when prescribed medicines are not available at 
the facility. These private for- profit drug outlets were then 
visited and administered the same survey instrument used 
at the facilities.
Data were collected on availability (having or not 
having the medicine in stock on the day of data collec-
tion, based on physical observation by data collectors) 
and price (in Kenyan Shillings—KES) of 27 NCD medi-
cine formulations and 9 medicine formulations for acute 
diseases. Price data (how much patients pay if they have 
to pay for the medicine out of pocket) were collected 
from the staff in charge of medicines at each facility. For 
each medicine, data were collected on the originator 
brand and the lowest priced generic. The selection 
of the 27 NCD medicines for this study was based on 
two criteria1: inclusion of the medicines in the Novartis 
Access portfolio as this study was part of a larger study 
of the Novartis Access programme2; the inclusion of the 
medicines in the STGs of the Ministry of Health. The 
acute disease medicine formulations included in this 
study are all on the EML of Kenya and have been used 
as reference medicines in evaluating the availability and 
price of medicines in health systems.34 These medicines 
were selected by a group of researchers from Boston 
University based on their frequency of use in primary 
care and their use in other research studies.13 14 20 All the 
study medicines were listed in the most recent STGs of 
the Ministry of Health. The list of medicines on which 
data were collected are shown in online supplementary 
appendix 1.
Patient and public involvement
Patients were not involved in the design or conduct of the 
study. Patients may be engaged after endline data collec-
tion to disseminate final study results at the county level 
and to the wider NCD patient community.
Data analysis
Data were analysed using SAS V.9.4 (The SAS Institute).40 
Three of the NCD medicines which were for cancer 
(anastrozole, letrozole and tamoxifen) were excluded 
from this analysis because cancer management in Kenya 
mainly occurs in tertiary health facilities which were not 
the focus of this study. Additionally, diclofenac 50 mg 
tablets were excluded from the analysis because it was 
the only acute disease medicine that was in the STG but 
not listed on the national EML. Inclusion of medicines 
in the EML was determined by their enlistment in either 
the 2010 or 2016 editions of the EML.25 41 Based on this 
definition, nine of the NCD medicines were included in 
the EML. The analysis focused on the number of observa-
tions and excluded missing data.
The following outcome measures were estimated: (1) 
the proportion of availability (defined as the proportion 
of healthcare providers having a branded or generic 
version of each medicine available in stock) and (2) the 
median price (and minimum and maximum prices) of 
each generic or originator medicine across healthcare 
providers. Availability for NCD medicines was assessed 
using two approaches. The first analysis focused only 
on NCD medicine formulations listed in the EML. In 
the second analysis, availability was analysed for 24 NCD 
medicine formulations which were listed in the most 
recent editions of STGs.30 42–45 The availability of study 
medicine formulations was evaluated by provider type 
and also by level of care. Differences in mean availability 
between acute and NCD medicines were estimated using 
the two- sample t- test.
Median, minimum and maximum prices of study medi-
cines were estimated for observations for which medicines 
were not given for free (ie, price was not equal to zero). 
All price analyses were conducted in September 2016 
KES. Using the supplier prices from the 2015 edition of 
the International Medical Products Price Guide (IMPPG) 
which is published by Management Sciences for Health 
as a reference, the median price ratio for each medicine 
formulation was estimated.46 Due to the limited avail-
ability of originator brands, median price ratios were 
estimated for only generics. Only 23 of the study medi-
cines had supplier prices reported in the IMPPG which 
was used for the median price ratio computation. First 
the prices from the IMPPG (in 2015 US dollars) were 
inflated to 2016 rates, using the average of 2015 and 2016 
annual inflation rates (0.7) obtained from the US infla-
tion calculator.47 The September 2016 price data were 
converted from KES to US dollars using 15 September 
2016 exchange rate of obtained from  xe. com. Median price 
ratios were compared among public, private non- profit 
and private for- profit drug stores, and across levels of care 
(levels 2, 3, 4 and 5) using analysis- of- variance with the 
Tukey- Kramer adjustment procedure to compare pairs of 
means. Differences in mean price ratios between acute 
and NCD medicines were estimated using the two- sample 
t- test. The proportion of facilities giving each medicine 
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Figure 1 Facility level mean proportion of availability by provider type for NCD medicines included in the EML, NCD medicines 
listed in STGs and acute medicines included in the EML. The box indicates the mean and the bars indicate the minimum and 
maximum. EML, Essential Medicines List; FP, private for- profit drug outlet; NCD, non- communicable disease; NP, private non- 
profit facility; PU, public facility; STG, Standard Treatment Guidelines.
for free was also estimated, stratified by provider type and 
level of care.
results
A total of 272 healthcare providers were surveyed—59 
public facilities, 78 private non- profit facilities and 135 
private for- profit drug outlets. There was 100% response 
rate from health facilities, while two of the private for- 
profit drug outlets declined to participate in the study. 
The total number of participating healthcare providers 
varied across study counties, from a minimum of 12 in 
Samburu to a maximum of 48 in Embu county (online 
supplementary appendix 2). More than half (n=77; 61%) 
of study facilities were level 2 (dispensaries), 18% (n=23) 
were level 3 (health centres), while 20.6% (n=26) were 
level 4 (primary referral facilities). There were few (n=5; 
4%) level 5 (secondary referral) facilities.
Medicines availability
We first present results on the availability of STG and EML 
medicines by provider type. This is followed by results on 
availability stratified by level of care. Finally, we focus on 
how availability patterns indicate non- compliance with 
the EML.
Availability by provider type
Figure 1 compares the availability of NCD medicines listed 
in the EML, NCD medicines listed in the STGs and medi-
cines for acute conditions listed in the EML, by provider 
type. For each of the three categories of medicines, avail-
ability was highest in private for- profit drug outlets (61.7, 
29.3% and 66.9% for NCD medicines on the EML, NCD 
medicines on the STG and acute disease medicines) 
compared with public and non- profit providers. Across 
all provide types, availability of medicines listed in the 
EML was higher than availability of medicines listed in 
the STGs. Comparing medicines on the EML, the mean 
proportion of NCD medicine availability (0.55) was not 
significantly different from the mean proportion of acute 
medicine availability (0.61) (p=0.55). Considering medi-
cines in the STGs, the overall mean proportion of NCD 
medicine availability (0.25) was significantly lower than 
the overall mean proportion of acute medicine avail-
ability (0.61); p<0.0001. Online supplementary appendix 
3 presents the overall availability of each study medicine 
disaggregated by provider type and branded vs generic 
formulations. Generally, generics were more common 
than originator brands across all providers. Only two orig-
inator brands of study medicines were available in public 
facilities compared with 19 in private non- profit, and 
21 in private for- profit drug outlets. Several medicines 
included in the EML had a proportion of availability of 
over 50%. However, salbutamol, an important medicine 
for asthma relief had an availability of less than 40% 
across the different types of providers. Thirteen medi-
cines had very low availability including CVD medicines 
such as bisoprolol, ramipril, simvastatin, valsartan and 
diabetes medicines such as glimepiride.
Availability by level of care
Figure 2 presents the proportion of availability of NCD 
medicines listed in the STGs and acute disease medicines 
(listed in the EML) by level of care. For NCD medicines 
in the STGs availability increases with increasing level of 
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Figure 2 Facility level mean proportion of availability by level of care for medicines listed in the Standard Treatment Guidelines 
and acute disease medicines. The box indicates the mean and the bars indicate the minimum and maximum. L2, level 2 
facilities; L3, level 3 facilities; L4, level 4 facilities; L5, level 5 facilities; N, number of medicines surveyed.
care, from 16.1% at level 2 facilities to 31.7% at level 5 
facilities. A similar trend was observed for acute disease 
medicines. At each level of care, the availability of acute 
disease medicines was more than two times the availability 
of NCD medicines listed in the STGs. The findings at level 
5 facilities should be interpreted with caution because of 
the small sample size—only five facilities were surveyed at 
this level of care.
Online supplementary appendix 4 presents the avail-
ability of study medicines by county. The mean propor-
tion of availability of study medicines ranges from 0.24 in 
West Pokot to 0.42 in Makueni.
Non-compliance of public and non-profit facilities with the EML
Twelve of the NCD medicines in this study were not on the 
EML. However, each of these medicines was found at all 
levels of care. The proportion of health facilities stocking 
these medicines ranged from 0.01 to 0.2. As mentioned 
earlier, all of the study NCD medicines included in the 
EML were assigned level 4 and above except salbutamol 
inhaler which was assigned level 2 and above. However, 
more than half of levels 2 and 3 facilities were stocking 
four of these medicines (amitriptyline 25 mg, furose-
mide 40 mg, metformin 500 mg and omeprazole 20 mg) 
(online supplementary appendix 3). Among acute medi-
cines, diazepam 5 mg was restricted to level 4 and above, 
however, the proportion of level 2 and level 3 facilities 
stocking this medicine were 0.5 and 0.6, respectively.
Medicine prices
In this section, we first present results on medicine prices 
by provider type, followed by results on prices stratified 
by level of care.
Medicine prices by provider type
There were wide variations in medicine prices across and 
within provider types. The within provider type variations 
appeared to be more pronounced in private drug outlets 
compared with public sector facilities. For example, the 
price of 1 g vial of generic ceftriaxone ranged from 30 to 
800 KES in private drug outlets, 10 to 550 in private not- 
for- profit facilities and 50 to 400 in public facilities.
The mean proportion of public facilities giving medi-
cines for free (0.47) was significantly higher than the 
mean proportion of private non- profit facilities giving 
medicines for free (0.09) (p<0.0001). For example, 
generic metformin 500 mg tablets/caps was provided for 
free at 38.5% (n=15/39) of public facilities and 14.9% 
(n=7/47) of private non- profit facilities. Drug outlets did 
not offer any medicines for free. There was large vari-
ability in the free provision of medicines among public 
health facilities which was unrelated to county (data not 
shown). The mean proportion of non- profit facilities 
giving NCD medicines for free (0.05) was significantly 
less than the mean proportion giving acute medicines for 
free (0.18), p<0.0001. However, this difference was not 
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Figure 3 Mean price ratios of non- communicable disease medicines and acute disease medicines by provider type. The box 
indicates the mean and the bars indicate the minimum and maximum. FP, private of- profit drug outlet; N, number of medicines 
surveyed; NP, private non- profit facility; PU, public facility.
significantly different in public facilities (0.45 for NCD 
medicines and 0.54 for acute medicines), p=0.3119.
The median price ratio ranged from 0.6 for paracetamol 
syrup in private for- profit drug outlets to 8.3 for simvas-
tatin 20 mg tablets/caps in private non- profit health facil-
ities. There was more variability in median price ratios for 
NCD medicines (figure 3). The mean price ratio was 2.29 
in the public sector, 3.61 in the private non- profit sector, 
and 2.95 in drug outlets (table 1 and figure 3). The mean 
price ratio of NCD medicines (2.1) was not significantly 
different from the mean price ratio of acute medicines 
(2.0) in public facilities p=0.3517. However, the mean 
price ratio of NCD medicines was significantly higher 
than the mean price ratio of acute medicines in non- 
profit facilities (4.1 vs 2.0, respectively), p=0.0094; and in 
drug outlets (3.5 vs 1.7), p=0.0014.
Medicine prices by level of care
Online supplementary appendix 5 presents the propor-
tion of facilities dispensing medicines for free and the 
median prices of medicines by level of care. There were 
wide price variations across the different levels of care and 
within each level of care. Even though levels 2 and 3 facili-
ties were expected to be providing medicines for free, the 
proportion of level 2 facilities which gave specific medi-
cines for free ranged from none to 42%. The proportion 
of level 3 facilities that provided medicines for free ranged 
from none to 67%. More levels 2 and 3 facilities provided 
medicines for free compared with level 4 facilities. There 
were no clear trends in price ratios by level of care.
DIsCussIOn
This study has revealed important findings on the avail-
ability and price of NCD medicines in Kenya. It is the first 
study to report on disparities in availability of medicines 
by level of care within public and non- profit facilities and 
take into account the EML restriction on medicines with 
respect to level of care.
Medicines availability for nCD and acute conditions
While the availability for many EML medicines was 
higher than 50%, availability was far below the interna-
tional target of 80% availability.15 48 This is concerning 
by copyright.
 on January 18, 2021 at U











pen: first published as 10.1136/bm





7Ashigbie PG, et al. BMJ Open 2020;10:e035132. doi:10.1136/bmjopen-2019-035132
Open access
Table 1 Percentage of healthcare providers dispensing medicines free of charge and median price ratios by provider type 
(using Management Sciences for Health supplier prices as a reference)
Medicine tablets or 
capsules except otherwise 
noted









dispensed for free 
(number) Public Non- profit Drug stores
Medicines for CVD
  Amlodipine 10 mg 2 50 (1) 12 8.3 (1) 1.3 2.7 2.7
  Amlodipine 5 mg 17 17.6 (3) 16 0 2.3 6.3 5.0
  Atenolol 50 mg 31 32.3 (10) 38 15.8 (6) – 3.7 4.6
  Bisoprolol 10 mg 0 – 1 0 – 3.4 –
  Bisoprolol 5 mg 1 0 (0) 0 – – – –
  Captopril 25 mg 0 – 3 0 – 4.4 2.0
  Furosemide 40 mg 41 43.9 (18) 57 12.3 (7) 1.6 3.3 3.3
  Hydrochlorothiazide 50 mg 12 58.3 (7) 16 0 2.3 6.4 4.7
  Ramipril 10 mg 0 – 1 0 – – –
  Ramipril 5 mg 0 – 1 0 – – –
  Simvastatin 20 mg 0 – 1 0 – 8.3 5.7
  Valsartan 80 mg 0 – 1 0 – – –
Medicines for diabetes
  Glibenclamide 5 mg 34 35.3 (12) 44 11.4 (5) 3.5 5.3 5.3
  Glimeperide 1 mg 0 – 1 0 – – –
  Glimeperide 2 mg 0 – 3 0 – – –
  Glimeperide 4 mg 0 – 3 0 – – –
  Metformin 1000 mg 0 – 1 0 – 2.6 1.3
  Metformin 500 mg 39 38.5 (15) 47 14.9 (7) 2.0 3.3 3.3
Medicines for asthma
  Salbutamol 100 MCG/DOS 
inhaler
24 41.7 (10) 35 14.3 (5)
1.1 1.0 1.4
Other NCD medicines
  Amitriptyline 25 mg 40 45 (18) 50 16 (8) 1.3 3.5 2.3
  Omeprazole 20 mg 45 35.6 (16) 65 15.4 (10) 3.5 3.5 3.5
Acute medicines
  Amoxicillin 250 mg 
Dispersible tab 21 52.4 (11) 27 22.2 (6) 1.4 0.9 0.9
  Amoxicillin 250 mg 41 43.9 (18) 53 18.9 (10) 1.9 1.9 1.9
  Amoxicillin 500 mg 7 71.4 (5) 37 13.5 (5) 1.5 1.7 1.7
  Ceftriaxone 1 g/vial Inj 40 40.0 (16) 57 12.3 (7) 2.9 3.7 1.7
  Ciprofloxacin 500 mg 15 40.0 (6) 45 8.9 (4) 2.7 2.7 2.7
  Co- trimoxazole 8+40 mg/
mL Susp. 31 67.7 (21) 51 27.5 (14) 1.1 2.1 1.7
  Diazepam 5 mg 34 44.1 (15) 51 21.6 (11) 3.7 2.1 2.1
  Paracetamol 24 mg/mL 
Susp 44 75.0 (33) 57 24.6 (14) 1.0 1.0 0.6
Mean 43.8 8.7 2.1 3.4 2.9
Medicines on the EML (2010 or 2016) are highlighted in bold.
*Refers to the number of facilities that have the medicine in stock and which reported a price for it.
CVD, cardiovascular diseases; EML, Essential Medicines List; NCD, non- communicable disease.
in particular for NCD medicines. We found significantly 
lower availability of NCD medicines listed in the STGs 
compared with medicines for acute conditions. This is 
despite the fact that one- half of total hospital admissions 
and over 55% of hospital deaths in Kenya are due to 
NCDs.4 The mean availability of NCD medicines included 
by copyright.
 on January 18, 2021 at U











pen: first published as 10.1136/bm





8 Ashigbie PG, et al. BMJ Open 2020;10:e035132. doi:10.1136/bmjopen-2019-035132
Open access 
in the STGs was two to three times lower than those found 
in other studies in Kenya.13 20 21 The low availability of 
some of these NCD medicines may indicate low demand, 
or the preference of prescribers and patients for other 
therapeutic options within the same classes of medicines 
which were not assessed in our study. Considering the 
high burden of NCDs globally, and the rapidly increasing 
burden in LMICs, efforts are needed to ensure the reli-
able supply of NCD medicines in health facilities at all 
levels in Kenya.
Our study assessed the availability of medicines specifi-
cally at levels 2, 3, 4 and 5 facilities with availability higher 
at higher levels of care (though the differences were not 
statistically significant). Among the programmatic objec-
tives of the EML is the promotion of appropriate use of 
medicines. For this reason, several NCD medicines are 
limited to certain levels of care. Despite the limitation of 
NCD medicines to level 4 facilities and above, we found 
many of these medicines in several levels 2 and 3 facilities 
suggesting there is demand for NCD medicines at these 
lower level facilities. If the barrier to availability is the 
limitation of NCD medicines to level 4 facilities and above, 
then additional measures such as building the capacity of 
lower level care facilities to provide these medicines may 
be needed to ensure access. It is also important to note 
that 12 NCD medicine formulations that were not listed 
in the EML were available across all levels of care. Though 
the availability of these medicines were lower than those 
on the EML, it still raises the question of whether the 
EML is being implemented to its optimal potential in the 
country.
The generally low availability of originator brands, 
especially in the public sector is in line with interna-
tional recommendations to promote the use of generic 
medicines to increase efficiency in medicines expendi-
ture.32 49 50 Nonetheless, the limited availability of origi-
nator medicines in the public sector does not necessarily 
translate into higher rates of prescribing of generics. The 
2012 Pharmaceutical Country Profile of Kenya indicates 
that prescribing by International Non- proprietary Names 
(INN) is neither obligatory in the public sector nor in the 
private sector.51 Only 32% of medicines are prescribed by 
INN. Thus, it is important to promote prescribing by INN 
to further promote the use of generic medicines.
Prices of medicines
Though it is government policy to provide medicines 
for free at levels 2 and 3 facilities in Kenya, our findings 
suggest that there is a large variation in policy adherence 
and each facility decided whether to charge for the medi-
cines dispensed. Free dispensing varied across and within 
provider type (except for private drug outlets where no 
medicine was given for free), across level of care and by 
county. Patient knowledge of which facilities charge for 
medicines and which do not increases the complexity 
of efforts to find affordable medicines. There was no 
hospital at which paracetamol syrup and co- trimoxazole 
suspension, medicines frequently prescribed for chil-
dren, were given for free.
There were large price variations across and within 
provider type, level of care and county. Drug outlets and 
private non- profit facilities exhibited similar patterns 
in relation to pricing. Both types of providers charged 
higher prices than public facilities. Private non- profit 
providers were significantly less likely to offer medicines 
for free compared with public facilities. Additionally, 
the mean price ratios of NCD medicines were signifi-
cantly higher than the mean price ratio of acute medi-
cines in both private non- profit facilities and private 
drug outlets, though no significant differences were 
observed in the public sector. This may indicate relatively 
higher mark- ups on NCD medicines in non- profit and 
private drug outlets. Other studies have reported higher 
prices at private for- profit drug outlets.19 20 52 A study by 
Health Action International also demonstrated higher 
mark- ups on medicines in private non- profit providers.53 
The government of Kenya also charges import declara-
tion fees on medicines which may contribute to higher 
prices.51 Considering the low availability of NCD medi-
cines in public facilities, patients’ best option may have 
been to access their medicines at private non- profit facil-
ities and private drug outlets at higher prices. The high 
cost of NCD medicines has been shown to be a financial 
burden on households in Kenya.54 55
strengths and limitations
As mentioned earlier, this study is the first study that 
evaluates availability taking into consideration the level 
of care medicines are assigned in the EML. In addition, 
this study also evaluates availability separately NCD for 
medicines included in the EML and those included in the 
STGs, highlighting the differences between the two docu-
ments. The cross- sectional nature of the study does not 
allow us to assess trends in availability and price over time 
and precludes strong causal inference. While this study 
adds to the evidence base on the availability and prices of 
NCD medicines in Kenya, the findings may not be gener-
alisable to the whole country because the study counties 
were not randomly selected from across the country. In 
addition, we evaluated availability as binary variable (yes/
no) and did not count the quantity available. Further-
more, the sample of the private for- profit drug outlets was 
restricted to the nearest ones from public and non- profit 
facilities. Even though this sample is not representative 
of all private for- profit sector providers in each county, 
it allows studying the availability and prices consumers 
would encounter when referred from public and non- 
profit facilities.
COnClusIOn
We found evidence that the availability of NCD medicines 
in Kenya is significantly lower than the target level of 80%. 
Availability is poorest in the public sector, and gener-
ally highest in the private for- profit sector. Availability 
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increased with increasing level of care. Our findings 
suggest that NCD patients in Kenya do not have reliable 
access to NCD medicines, particularly at public health 
facilities. Increasing access at public facilities, particularly 
levels 2 and 3 facilities, should be a focus of the Kenyan 
government’s efforts to achieve universal health coverage. 
Pricing policies or guidelines may be useful to streamline 
medicine prices in the country.
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